BSD Medical is the world leader in technology for treatment of cancer using hyperthermia.
The new BSD-2000/3D system uses 3D-focused microwave energy to destroy cancerous tumors. This pioneering technology has already received four US patents, was recently patented in Europe, and expects to receive the CE Mark (approval by European Union regulatory authority) by mid-1999. The BSD-2000/3D system was designed through collaboration with the National Cancer Institute and is breakthrough technology capable of simultaneously providing hyperthermia therapy and MR imaging of diseased tissues.
BSDM's advanced deep heating cancer systems are currently under Investigational Device Exemption (IDE) approval status in the US and clinical trials are now in progress using hyperthermia in combination with radiation therapy and/or chemotherapy. If approved by the FDA, the BSD-2000/3D system could provide effective treatment for patients with large, deep tumors (such as breast, lung, colorectal, liver, cervical, bladder, stomach, and prostate).
In addition, BSDM has pioneered the use of microwave therapy for treatment of benign diseases of the prostate.
The value of treating cancer using hyperthermia is rapidly gaining acceptance in the medical community both in the U.S. and abroad. Installation of the first BSD-2000 3D/MR system was completed in August 1998. As of November 1998, BSDM had received orders totaling $1.6M for the new equipment line and a backlog of $200,000 in sales of the same for delivery in FY 1999. Such backlog continues to accrue as the company awaits approval of the CE Mark, now required for sales to all European Union countries.
For corporate and investor information, as well as more details on BSDM technology, please consult the company's Web site:
bsdmc.com
BSDM Corporate Profile:
biz.yahoo.com |
